Re:The Villain of CRISPR
by toomuchtodo on Monday January 25, 2016 @08:34PM
(#10971344)
Which is going to break down quickly when anyone can replicate those materials at little cost on their workbench.
[ Parent
| on HN ]
They do a pretty good job regulating drug imports that violate IP, and I suspect they will here as well. The materials in question will be complex human therapeutic compositions, not research materials. I strongly doubt people will be creating therapeutic CRISPR compositions at the workbench (which will also include sophisticated delivery and targeting molecular products).